Tomoyasu Kato Selected Research

Tomoyasu Kato Research Topics

Disease

73	Neoplasms (Cancer) 05/2024 - 02/2005
31	Uterine Cervical Neoplasms (Cancer of the Cervix) 05/2024 - 07/2009
21	Ovarian Neoplasms (Ovarian Cancer) 07/2023 - 09/2010
20	Carcinoma (Carcinomatosis) 03/2024 - 11/2003
15	Endometrial Neoplasms (Endometrial Cancer) 05/2024 - 09/2010
7	Adenocarcinoma 12/2023 - 12/2009
7	Carcinosarcoma 10/2023 - 02/2012
5	Neoplasm Metastasis (Metastasis) 08/2021 - 05/2017
4	Breast Neoplasms (Breast Cancer) 03/2024 - 02/2012
4	Ovarian Epithelial Carcinoma 03/2024 - 10/2020
4	Leiomyosarcoma 05/2023 - 12/2019
4	Endometriosis 02/2021 - 12/2008
3	Myoma 02/2024 - 01/2023
3	Hemorrhage 01/2024 - 10/2019
3	Lymphatic Metastasis 10/2023 - 10/2019
3	Residual Neoplasm 08/2023 - 02/2012
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2021 - 10/2012
3	Ascites 01/2021 - 01/2017
3	Cicatrix (Scar) 09/2020 - 10/2019
2	Carcinogenesis 10/2023 - 05/2019
2	Disease Progression 01/2023 - 01/2018
2	Infections 01/2023 - 03/2020
2	Emergence Delirium 11/2022 - 01/2021
2	Endometrioid Carcinoma 05/2022 - 03/2020
1	Microsatellite Instability 05/2024
1	Protein Deficiency 01/2023
1	Delirium 11/2022
1	Ulcer 02/2022
1	Fistula 02/2022
1	Thymoma (Thymic Carcinoma) 10/2021

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 12/2023 - 01/2018
9	MicroRNAs (MicroRNA)IBA 02/2024 - 10/2017
8	PlatinumIBA 05/2024 - 01/2014
8	DNA (Deoxyribonucleic Acid)IBA 10/2023 - 05/2019
6	Biomarkers (Surrogate Marker)IBA 12/2023 - 10/2017
6	human ERBB2 proteinIBA 10/2023 - 05/2012
4	AntigensIBA 07/2023 - 10/2012
4	Phosphotransferases (Kinase)IBA 06/2023 - 01/2016
4	ErbB Receptors (EGF Receptor)IBA 02/2023 - 05/2012
4	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 05/2017
3	RNA (Ribonucleic Acid)IBA 09/2023 - 01/2018
3	Estrogen ReceptorsIBA 06/2023 - 10/2019
3	Paclitaxel (Taxol)FDA LinkGeneric 10/2019 - 10/2016
2	eribulin FDA Link 03/2024 - 01/2014
2	Epithelial Cell Adhesion MoleculeIBA 03/2024 - 01/2019
2	MesothelinIBA 10/2023 - 11/2022
2	Tumor Biomarkers (Tumor Markers)IBA 07/2023 - 10/2012
2	LigandsIBA 06/2023 - 12/2022
2	Folate Receptor 1IBA 01/2023 - 11/2022
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2023 - 11/2022
2	Exonucleases (3' 5' Exonuclease)IBA 01/2023 - 05/2022
2	Yi-Gan SanIBA 11/2022 - 01/2021
2	polysulfideIBA 08/2021 - 01/2021
2	Hyaluronic Acid (Hyaluronan)IBA 03/2020 - 02/2019
2	Indicators and Reagents (Reagents)IBA 01/2018 - 02/2005
2	Carboplatin (JM8)FDA LinkGeneric 11/2017 - 10/2016
2	Hormones (Hormone)IBA 05/2012 - 02/2012
1	Immune Checkpoint InhibitorsIBA 05/2024
1	Surface Antigens (Surface Antigen)IBA 05/2024
1	Glycoproteins (Glycoprotein)IBA 05/2024
1	pembrolizumabIBA 05/2024
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2024
1	Alanine Transaminase (SGPT)IBA 01/2024
1	TransferasesIBA 01/2024
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 10/2023
1	Transcription Factors (Transcription Factor)IBA 10/2023
1	ChemokinesIBA 10/2023
1	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2023
1	MART-1 AntigenIBA 08/2023
1	Progesterone Receptors (Progesterone Receptor)IBA 06/2023
1	TropomyosinIBA 06/2023
1	Phenobarbital (Luminal)FDA Link 06/2023
1	Testosterone (Sustanon)FDA Link 05/2023
1	Androgen Receptors (Androgen Receptor)IBA 05/2023
1	Epidermal Growth Factor (EGF)IBA 02/2023
1	tyrosine receptor (receptor, tyrosine)IBA 02/2023
1	DNA Polymerase IIIBA 01/2023
1	trastuzumab deruxtecanIBA 01/2023
1	Immunoconjugates (Immunoconjugate)IBA 01/2023
1	Topoisomerase I InhibitorsIBA 01/2023
1	NucleotidesIBA 01/2023
1	Folic Acid (Vitamin M)FDA LinkGeneric 11/2022
1	HydrogelsIBA 07/2022
1	AcidsIBA 05/2022
1	Bevacizumab (Avastin)FDA Link 02/2022
1	BI 2536IBA 01/2022
1	prexasertibIBA 01/2022
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 10/2021

Therapy/Procedure

30	Therapeutics 05/2024 - 09/2010
21	Hysterectomy 05/2024 - 11/2003
18	Drug Therapy (Chemotherapy) 05/2024 - 09/2010
15	Brachytherapy 01/2023 - 05/2016
11	Radiotherapy 07/2022 - 09/2011
8	Lymph Node Excision (Lymph Node Dissection) 05/2024 - 09/2010
5	Adjuvant Chemotherapy 05/2024 - 09/2010
5	Neoadjuvant Therapy 06/2023 - 11/2017
4	Chemoradiotherapy 01/2023 - 09/2010
3	Salpingo-oophorectomy 05/2023 - 07/2020
2	Aftercare (After-Treatment) 07/2023 - 09/2020
1	Re-Irradiation 02/2022